Bio-Techne Earnings Call Transcripts
Fiscal Year 2026
-
Pharma and China are driving growth, while biotech and academic markets are rebounding as funding returns. Fiscal 2026 guidance is cautious but optimistic, with margin expansion expected through differentiated products and operational improvements.
-
Celebrating its 50th anniversary, the company is leveraging a diversified portfolio and four growth verticals to drive future growth. Strong performance in large pharma and improving biotech funding support confidence in mid-single digit growth by fiscal 2026, while margin expansion and strategic M&A remain key priorities.
-
Q2 revenue was flat year-over-year, with strong pharma demand offset by biotech and academic softness. Adjusted operating margin expanded to 31.1%, and strategic growth verticals now represent nearly half of revenue. Outlook calls for mid-single-digit underlying growth as headwinds abate.
-
A diversified life sciences company reported $1.2B in 2025 revenue, driven by consumables and strong positions in protein sciences and spatial biology. Despite short-term headwinds from cell therapy customer transitions, innovation and M&A remain central to growth, with improving biotech and academic markets supporting a positive outlook.
-
Organic revenue declined 1% year-over-year in Q1, with strong large pharma demand offset by cell therapy timing and biotech softness. Adjusted operating margin expanded to 29.9%, and positive momentum is expected in the second half as headwinds ease.
Fiscal Year 2025
-
The business is leveraging its core reagents across four high-growth areas, with recent strong performance in large pharma, China, and product innovation. While cell therapy revenue faces a near-term dip due to Fast Track approvals, long-term prospects remain robust, and market normalization is expected by late 2026.
-
Pharma and academic markets have stabilized, supporting a more optimistic outlook for Biotech, though spending recovery will lag funding improvements. Two major cell therapy customers paused orders, impacting GMP revenue, but long-term commercial potential remains significant. ProteinSimple and Spatial Biology franchises are leading growth, with margin expansion expected in the second half.
-
Organic revenue declined 1% due to cell therapy headwinds, but large pharma and China showed strong growth. Biotech and academic markets are stabilizing, with funding visibility improving. Two major cell therapy customers' Fast Track status creates a temporary revenue gap, but long-term prospects remain strong.
-
Core growth was up 1% after adjusting for order timing, with large pharma and biotech showing strength, especially in the US, Europe, and China. Innovation and targeted grants expanded the customer base, while M&A remains a priority with capacity for further deals. Headwinds from GMP protein customers are expected to ease after Q4.
-
Pharma and China markets are showing strong growth, while academic and biotech segments are stabilizing. Cell therapy faces short-term headwinds from fast-tracked customers but offers significant long-term potential. Growth verticals and new integrations position the business for double-digit growth as markets normalize.
-
Organic revenue declined 1% due to GMP customer order timing, but underlying growth and momentum improved across academic, pharma, and China markets. Product innovation in Spatial and ProteinSimple, strategic investments, and margin management position the business for recovery and a return to double-digit growth as markets stabilize.
-
Organic growth was impacted by a $7M GMP protein headwind, but underlying trends in pharma and biotech were positive. New product launches and operational efficiencies are expected to drive growth and margin expansion, with China and spatial biology showing improving momentum.
-
The meeting covered director elections, executive compensation, and auditor ratification, with all proposals passing and a quorum of 90% of shares represented. No shareholder questions were received during the Q&A session.
-
Strong recurring revenue and strategic investments in automation, spatial biology, and cell therapy have driven above-market growth, with recent performance buoyed by pharma and China. Despite near-term uncertainty in biotech and academia, management expects stabilization and long-term growth as market headwinds subside.
-
Pharma rebounded to double-digit growth, while biotech and U.S. academic markets faced funding headwinds. Growth pillars like cell therapy and proteomics are expanding, and margin improvements are targeted through portfolio optimization and productivity. M&A and buybacks remain strategic priorities.
-
Q4 organic growth reached 3%, led by strong pharma and instrumentation, while China saw a temporary boost from tariff-related pull-ins. Strategic divestitures and investments in cell therapy and proteomics support margin expansion, with low single-digit growth and 100–200 basis points margin improvement targeted for the year.
-
Q4 saw 3% organic revenue growth and strong biopharma demand, offset by cautious biotech and academic spending amid funding uncertainties. The Exosome Diagnostics divestiture will boost margins, and low single-digit growth is expected until market headwinds subside.
-
Q3 saw 6% organic growth, led by strong large pharma and robust European academic markets, while US academic and China remained challenging. Tariff risks are well-mitigated, and instrumentation and spatial biology segments are performing well. Share repurchases continue alongside a focus on strategic M&A.
-
Pharma delivered strong growth, while academic and biotech segments faced macro-driven volatility. China is showing early signs of recovery, and spatial and proteome platforms remain key growth drivers. Margin expansion continues, with a long-term target above 35%.
-
A differentiated portfolio and strong innovation pipeline drive growth across protein sciences, diagnostics, and spatial biology, with 2024 revenue at $1.2 billion and 6% organic growth year-to-date. Strategic focus remains on analytical platforms, cell therapy, and precision diagnostics, supported by robust sustainability and governance initiatives.
-
Solid quarterly growth was driven by protein science and cell and gene therapy, while large pharma outperformed and biotech remained flat. Operational efficiencies maintained strong margins, and tariff risks were mitigated. Ongoing market and policy uncertainties shape a cautious outlook.
-
Q3 delivered 6% organic revenue growth and a 34.9% adjusted operating margin, led by strong pharma demand and operational efficiencies. Tariff and NIH funding uncertainties are expected to slow Q4 growth, but mitigation strategies are in place and long-term double-digit growth is anticipated.
-
Academic market disruption from NIH policy changes caused a brief slowdown, but growth is rebounding as funding resumes and priorities shift toward chronic disease research. Biopharma demand is strong, with large pharma and China both showing early signs of recovery and sustained momentum.
-
NIH funding uncertainty has caused a temporary pause in academic spending, but long-term impact is expected to be limited, with recent policy shifts reducing risk. Pharma and biotech are recovering faster than anticipated, GMP proteins and cell therapy platforms are driving growth, and margin expansion is expected as revenue rebounds.
-
A diversified life science tools provider leverages a robust core portfolio and high-growth verticals, driving mid-teens growth and high margins. Strategic investments, operational optimization, and targeted M&A have positioned the company to outpace the market and capitalize on megatrends like proteomics and cell and gene therapy.
-
Q2 delivered 9% organic revenue growth, driven by biopharma recovery, GMP reagents, and spatial biology. Adjusted operating margin rose to 30.1%, and guidance for the second half remains strong despite FX headwinds. Large pharma and cell/gene therapy momentum continue, with China expected to return to growth.
-
The conference highlighted a robust, innovation-driven strategy focused on three growth vectors: biological discovery, advanced therapeutics, and precision diagnostics. Despite macroeconomic headwinds, the company achieved steady growth, launched new products, and maintained strong financial health, with M&A as a key priority.
-
Q1 FY2025 delivered 4% organic revenue growth, led by diagnostics and spatial biology, with strong cell and gene therapy and molecular diagnostics performance. Margins faced headwinds from product mix and incentive comp, but cost controls and productivity initiatives support future expansion.
Fiscal Year 2024
-
Q1 growth outpaced the market, with strong momentum in GMP reagents, China recovery, and biotech funding. Margins are set to expand in the second half as product mix improves and operational efficiencies take hold. Strategic M&A, notably Wilson Wolf and Lunaphore, are expected to drive future growth and high-margin pull-through.
-
Recent results show strong growth in GMP proteins and cell/gene therapy, with robust funding trends and expanding market share. Strategic partnerships, product innovation, and disciplined M&A are driving momentum, while geographic and regulatory shifts are seen as net positives for future growth.
-
Leadership is focused on strategic clarity, operational efficiency, and disciplined M&A. Strong growth in GMP proteins and cell/gene therapy is supported by rebounding funding, while new product launches like Leo are set to drive future growth and margin expansion.
-
Q1 saw 4% revenue growth, strong diagnostics, and improved margins from operational efficiencies. AI-driven designer proteins and automation are key innovation drivers, while cell therapy, spatial biology, and liquid biopsy offer significant growth opportunities. M&A remains disciplined and targeted.
-
Leadership confirmed the strength of all growth verticals after a strategic review, divested non-core assets, and provided a cautious but optimistic fiscal 2025 outlook. Growth is expected from biopharma funding, China stimulus, and increased R&D spending, with innovation in proteomics, GMP, and diagnostics driving future performance.
-
Leadership highlighted strong positioning across all growth verticals, with Diagnostics and Genomics leading growth. Fiscal Q4 met expectations, and 2025 is expected to see accelerating recovery, driven by innovation in spatial biology, diagnostics, and cell/gene therapy.
-
Management highlighted a solid strategy leveraging core reagents and four growth pillars, with strong Diagnostics and Genomics performance and robust demand for new platforms like COMET. Biopharma and China markets are stabilizing, and 2025 guidance anticipates accelerating growth as market recovery unfolds.
-
Fourth quarter revenue grew 2% year-over-year, driven by strong performance in molecular diagnostics and spatial biology, despite ongoing market headwinds. Fiscal 2025 is expected to see gradual recovery, with margin improvement in the second half as end markets normalize.
-
Strong growth in diagnostics, genomics, and cell/gene therapy verticals offset pressures in protein sciences. Recurring consumables revenue and operational efficiencies support robust margins, while M&A remains a disciplined priority. China and biopharma funding trends are key watchpoints.
-
The event highlighted strong ESG progress, a diversified and fast-growing portfolio, and a strategy focused on innovation, automation, and high-growth verticals. Recent acquisitions and product launches are driving market outperformance and robust financial targets.
-
The presentation highlighted a mission-driven approach, strong sustainability initiatives, and a diversified business model with core products and four high-growth verticals. Strategic acquisitions, innovation, and integration of AI drive expansion, with robust financial targets and market outperformance.